18 F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience

• Published in: Journal of Nuclear Medicine Vol. 61; no. 4; pp. 505 - 511
• Main Authors: Maurer, Gabriele D, Brucker, Daniel P, Stoffels, Gabriele, Filipski, Katharina, Filss, Christian P, Mottaghy, Felix M, Galldiks, Norbert, Steinbach, Joachim P, Hattingen, Elke, Langen, Karl-Josef
• Format: Journal Article
• Language: English
• Published: United States 01.04.2020
• Subjects: pseudoprogression; glioma; treatment-related changes; 18F-FET PET; tumor progression
• ISSN: 0161-5505; 1535-5667; 2159-662X
• DOI: 10.2967/jnumed.119.234757

In glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TRCs) remains challenging. Difficulties in classifying imaging alterations may result in a delay or an unnecessary discontinuation of treatment. PET using -(2- F-fluoroethyl)-l-tyrosine ( F-FET) has been shown to be a useful tool for detecting TP and TRCs. We retrospectively evaluated 127 consecutive patients with World Health Organization grade II-IV glioma who underwent F-FET PET imaging to distinguish between TP and TRCs. F-FET PET findings were verified by neuropathology (40 patients) or clinicoradiologic follow-up (87 patients). Maximum tumor-to-brain ratios (TBR ) of F-FET uptake and the slope of the time-activity curves (20-50 min after injection) were determined. The diagnostic accuracy of F-FET PET parameters was evaluated by receiver-operating-characteristic analysis and χ testing. The prognostic value of F-FET PET was estimated using the Kaplan-Meier method. TP was diagnosed in 94 patients (74%) and TRCs in 33 (26%). For differentiating TP from TRCs, receiver-operating-characteristic analysis yielded an optimal F-FET TBR cutoff of 1.95 (sensitivity, 70%; specificity, 71%; accuracy, 70%; area under the curve, 0.75 ± 0.05). The highest accuracy was achieved by a combination of TBR and slope (sensitivity, 86%; specificity, 67%; accuracy, 81%). However, accuracy was poorer when tumors harbored isocitrate dehydrogenase ( ) mutations (91% in -wild-type tumors, 67% in -mutant tumors, < 0.001). F-FET PET results correlated with overall survival ( < 0.001). In our neurooncology department, the diagnostic performance of F-FET PET was convincing but slightly inferior to that of previous reports.